Medium impact
Guillain-Barre Syndrome Treatments (CPB 0732, reviewed 2026-10-21)
Aetna·Identified Oct 26, 2026
HCPCS Q3027 is officially defined as "Injection, interferon beta-1a, 1 mcg for intramuscular use." HCPCS Q3027 is referenced in 1 tracked payer policy change from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q3027 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.